News

Sagimet CEO David Happel says oral denifanstat could sharply cut antibiotic use in acne and be used before patients ever need isotretinoin.

GLP-1 drug spending surges and rewires diabetes care as session at teh 2026 PBMI Annual National Conference spotlight PBM disruption, AI-driven actionable data, and new state reporting rules.

Sagimet Biosciences’ denifanstat oral acne pill shows rapid, sustained lesion cuts and higher clear-skin rates in phase 3, offering an antibiotic-sparing option.

A number of pharmacy benefit managers are creating programs geared to the healthcare needs of women.

Implementation costs, structural pressures and the labor-intensive nature of healthcare mean that artificial intelligence is unlikely to dramatically lower its costs, at least in the short term.

Real-world research using the PEDISTAD registry makes up for the gap left by relatively low enrollment of children with skin of color in the pivotal trials of Dupixent (dupilumab).

New guidelines for acute low back pain favors self-care, NSAIDs, physical therapy and acupuncture over routine imaging and first-line opioids.

Breakthroughs in 2026 dermatology spotlight oral psoriasis drugs nearing biologics, weight-loss combos for PsA, personalized mRNA melanoma vaccines and expanding OTC acne options.

Direct-to-consumer drug programs hold the promise of cheaper GLP-1s and other drugs, but buying drugs outside insurance benefits may be more costly— and risky — in the long run.

Alison Pritchard, Ph.D., of Kennedy Krieger Institute, explains how ADHD and sleep problems reinforce each other in children and why clinicians should set clear expectations with caregivers before treatment begins.

The trade group argues CMS exceeded its authority with GLOBE, a Medicare Part B model tying drug rebates to prices in 19 other countries.

Blood RNA risk score from 31 small RNAs flags Lung Cancer in smokers up to 10 years early, potentially guiding earlier LDCT screening.

The CEO and founder of a digital behavior company has advice for health plans considering asynchronous behavioral health services like those that his company provides.

In this interview, Melody Chang, RPh, BCOP, MBA, vice president of pharmacy operation at the American Oncology Network, discusses the network's pharmacy strategy and priorities.

The purchase comes as the "big 3" drug wholesalers are coming under scrutiny for their market dominance and the possible perils of vertical integration.

High prices and cutbacks in ACA and Medicaid coverage leave many patients unable to medical bills.

In this discussion, Heather Burrell-Ward, M.D., provides an overview of her recent study that found TMS aimed at the default mode network improved processing speed in schizophrenia.

Rand researchers identify standardizing supplemental benefits, limiting the number of plans an insurer can market and reforming broker commissions as policy proposals that would benefit beneficiaries while not harming the government or the plans.

Reimagine Care and Dan Nardi scale CAR-T programs with remote cancer care, AI triage and nurses, as the Cureety partnership tackles staffing and access.

Biosimilars can cost $600 a month versus $6,000 for branded rivals, but PBM rebate incentives push formularies toward pricier drugs, says Christine Johnston.

Dan Nardi shares how Reimagine Care uses AI triage and connected devices to scale outpatient cancer support, enabling faster, personalized symptom monitoring.

In this interview, Jordan Herring, Ph.D., and Carlos E. Rodriguez-Diaz, Ph.D., MPHE, MCHES, discuss their study, which found a 16.8% increase in HIV incidence rates among Hispanic populations in antisanctuary counties after 2018 immigration policy shifts.

Metabolic dysfunction-associated steatotic liver disease (MASLD) may differ biologically from obesity-linked MASH, a mouse study suggests, with salt driving liver inflammation without obesity.

In this discussion, Ohio State economist Eric Seiber, Ph.D., explains how inconsistent claims-data definitions can skew estimates of first-episode psychosis and why standardization matters for early treatment and sustainable payment models.

CMS’ mandatory GLOBE drug model ties some Medicare Part B rebates to global prices, but cuts projected savings sharply amid shifting Part D premiums.

Bill Kerr of Avalon Heath Solutions says incorporating Z codes into CPT codes for lab and genetic testing would add needed specificity, reduce waste and possibly head off fraud.

States have to turn that information into medical frailty determinations that are clinically credible, consistent, and workable across large Medicaid populations.

A meta-analysis found steatotic liver disease in 75% of patients with sleep-disordered breathing and that CPAP lowered liver enzymes but not liver fat.